Opus Genetics

BiotechDurham

Acquired by Ocuphire Pharma, 2024, terms not disclosed

Clinical-stage gene therapy company developing treatments for inherited retinal diseases, traded on Nasdaq as IRD.

See the full company record.

Founders, funding history and recent signals. Free accounts open immediately.

If you want to work here anyway, tell us what you are after and Adam will pass it to the Opus Genetics team when there is a real fit.

Checking listed roles…